Candel Therapeutics, Inc. 8-K

What Happened

• Candel Therapeutics, Inc. announced the results of its Annual Meeting of Stockholders held on June 23, 2026. As of the April 24, 2026 record date there were 73,270,239 shares of common stock outstanding. Stockholders elected four Class II directors — Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci — to serve until the 2029 annual meeting. Stockholders also ratified the appointment of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Record date and shares outstanding: April 24, 2026; 73,270,239 shares outstanding.
• Director election vote totals:
  • Edward J. Benz, Jr., M.D.: For 24,897,348; Withheld 6,796,622; Broker non-votes 22,175,525.
  • Paul B. Manning: For 31,591,618; Withheld 102,352; Broker non-votes 22,175,525.
  • Maha Radhakrishnan, M.D.: For 31,047,706; Withheld 646,264; Broker non-votes 22,175,525.
  • Paul Peter Tak, M.D., Ph.D., FMedSci: For 31,414,668; Withheld 279,302; Broker non-votes 22,175,525.
• Auditor ratification vote: KPMG LLP ratified with For 53,543,020; Against 238,508; Abstain 87,967.
• No other matters were submitted or voted on at the meeting.

Why It Matters

• The election of the four Class II directors maintains the company’s board composition and governance continuity through 2029, which can be relevant to oversight of strategy and management. Ratification of KPMG as auditor confirms the selection of the firm responsible for auditing Candel’s financial statements for the 2026 fiscal year. Investors should note the vote counts and presence of broker non‑votes when assessing shareholder engagement and governance outcomes.